THERAPY DOSSIER · th-4352849e6823

SDF-1/CXCL12 infusion plus anti-scarring treatment (iron chelator and 8-bromo-cAMP)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21806987 ↗2011Reported benefit

Differential effect of aging on axon sprouting and regenerative growth in spinal cord injury.

RatSpinal cord injuryHemisection / partialWistarFemaleLocal infusion/injection into lesionAfter injury

Model: Partial dorsal hemisection at thoracic level T8

SDF-1 infusion restored age-impaired axon sprouting and anti-scarring treatment enhanced regeneration even in aged spinal cord injured rats.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…